Almirall S.A. (ALM) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.060x

Based on the latest financial reports, Almirall S.A. (ALM) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€88.75 Million ≈ $103.76 Million USD) by net assets (€1.48 Billion ≈ $1.72 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Almirall S.A. balance sheet quality to measure how much of total assets are equity-financed.

Almirall S.A. - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Almirall S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Almirall S.A. to evaluate the quality of earnings relative to operating cash generation.

Almirall S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Almirall S.A. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Rush Street Interactive Inc
NYSE:RSI
0.151x
Jiangxi Hongdu Aviation Industry Co Ltd
SHG:600316
0.092x
Sunway Construction Group Bhd
KLSE:5263
-0.090x
Corporación Inmobiliaria Vesta, S.A.B de C.V.
NYSE:VTMX
0.019x
Shareate Tools Ltd
SHG:688257
0.041x
TGS NOPEC Geophysical Company ASA
OL:TGS
0.129x
Ansell Limited
F:PD1A
0.031x
CLARIANT ADR 1/SF 4
F:CLRS
N/A

Annual Cash Flow Conversion Efficiency for Almirall S.A. (2005–2024)

The table below shows the annual cash flow conversion efficiency of Almirall S.A. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see ALM stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €1.49 Billion
≈ $1.74 Billion
€160.77 Million
≈ $187.95 Million
0.108x +69.08%
2023-12-31 €1.46 Billion
≈ $1.71 Billion
€93.48 Million
≈ $109.29 Million
0.064x -45.69%
2022-12-31 €1.32 Billion
≈ $1.54 Billion
€155.10 Million
≈ $181.33 Million
0.118x -35.32%
2021-12-31 €1.29 Billion
≈ $1.50 Billion
€233.85 Million
≈ $273.40 Million
0.182x +43.80%
2020-12-31 €1.30 Billion
≈ $1.52 Billion
€164.76 Million
≈ $192.63 Million
0.126x -41.38%
2019-12-31 €1.28 Billion
≈ $1.50 Billion
€276.15 Million
≈ $322.84 Million
0.216x +79.51%
2018-12-31 €1.19 Billion
≈ $1.39 Billion
€143.21 Million
≈ $167.43 Million
0.120x +2135.49%
2017-12-31 €1.13 Billion
≈ $1.33 Billion
€6.09 Million
≈ $7.12 Million
0.005x -92.22%
2016-12-31 €1.52 Billion
≈ $1.78 Billion
€105.06 Million
≈ $122.82 Million
0.069x -40.86%
2015-12-31 €1.46 Billion
≈ $1.71 Billion
€170.88 Million
≈ $199.78 Million
0.117x -75.81%
2014-12-31 €1.34 Billion
≈ $1.57 Billion
€646.93 Million
≈ $756.34 Million
0.483x +539.23%
2013-12-31 €888.33 Million
≈ $1.04 Billion
€67.11 Million
≈ $78.46 Million
0.076x -38.11%
2012-12-31 €923.67 Million
≈ $1.08 Billion
€112.75 Million
≈ $131.82 Million
0.122x +4.19%
2011-12-31 €854.71 Million
≈ $999.25 Million
€100.14 Million
≈ $117.07 Million
0.117x -45.02%
2010-12-31 €819.30 Million
≈ $957.85 Million
€174.60 Million
≈ $204.13 Million
0.213x -38.82%
2009-12-31 €751.00 Million
≈ $878.00 Million
€261.60 Million
≈ $305.84 Million
0.348x --
2008-12-31 €0.00
≈ $0.00
€233.10 Million
≈ $272.52 Million
x --
2007-12-31 €573.65 Million
≈ $670.66 Million
€179.03 Million
≈ $209.31 Million
0.312x +45.16%
2006-12-31 €763.21 Million
≈ $892.28 Million
€164.09 Million
≈ $191.84 Million
0.215x +36.46%
2005-12-31 €898.52 Million
≈ $1.05 Billion
€141.57 Million
≈ $165.51 Million
0.158x --

About Almirall S.A.

MC:ALM Spain Drug Manufacturers - Specialty & Generic
Market Cap
$2.78 Billion
€2.38 Billion EUR
Market Cap Rank
#5215 Global
#47 in Spain
Share Price
€11.10
Change (1 day)
-1.07%
52-Week Range
€10.14 - €13.82
All Time High
€16.89
About

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more